Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies
Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Mar 26, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of biopsy needle called SUREcore, which is designed to improve the way prostate biopsies are done. Prostate biopsies are important for detecting prostate cancer, and while MRI scans help doctors find areas to sample, sometimes the current needles don’t collect enough tissue for accurate results. The SUREcore needle aims to collect more tissue with each sample, which may help doctors better detect and understand prostate cancer.
To participate in this trial, you need to be a man over the age of 18 who is scheduled for a prostate biopsy. However, if you cannot give consent or have other health issues that could complicate the study, you may not be eligible. If you join the trial, you can expect to receive either the new SUREcore needle or the standard needle during your biopsy. This study is currently looking for participants, and your involvement could contribute to improving prostate cancer detection for others in the future.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Patient older than age of 18 undergoing prostate biopsy
- Exclusion Criteria:
- • Unable to consent
- • Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives
- • Prisoners
About University Of California, Davis
The University of California, Davis (UC Davis) is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials and studies. With a strong focus on interdisciplinary collaboration, UC Davis leverages its extensive expertise in medical research, education, and patient care to drive breakthroughs in various fields, including medicine, public health, and agriculture. The university's clinical trial programs emphasize rigorous scientific methodology and ethical standards, aiming to translate research findings into impactful treatments and improved patient outcomes. Through its state-of-the-art facilities and a dedicated team of researchers and healthcare professionals, UC Davis is at the forefront of transforming healthcare practices and addressing critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sacramento, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported